» Authors » Shweta S Chavan

Shweta S Chavan

Explore the profile of Shweta S Chavan including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 28
Citations 1035
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ziegler J, Hechtman J, Rana S, Ptashkin R, Jayakumaran G, Middha S, et al.
Nat Commun . 2025 Jan; 16(1):136. PMID: 39746944
Microsatellite instability (MSI) is a critical phenotype of cancer genomes and an FDA-recognized biomarker that can guide treatment with immune checkpoint inhibitors. Previous work has demonstrated that next-generation sequencing data...
2.
Taniguchi H, Chavan S, Chow A, Chan J, Mukae H, Rudin C, et al.
Front Immunol . 2024 Mar; 15:1348982. PMID: 38533509
Introduction: Immune checkpoint blockade (ICB) with or without chemotherapy has a very modest benefit in patients with small cell lung cancer (SCLC). SCLC tumors are characterized by high tumor mutation...
3.
Chow A, Uddin F, Liu M, Dobrin A, Nabet B, Mangarin L, et al.
Immunity . 2022 Dec; 56(1):93-106.e6. PMID: 36574773
Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies. CD39 expression is a promising surrogate of tumor-reactive CD8 T cells. Here, we comprehensively profiled CD39 expression in...
4.
Taniguchi H, Caeser R, Chavan S, Zhan Y, Chow A, Manoj P, et al.
Cell Rep . 2022 May; 39(7):110814. PMID: 35584676
Small cell lung cancers (SCLCs) have high mutational burden but are relatively unresponsive to immune checkpoint blockade (ICB). Using SCLC models, we demonstrate that inhibition of WEE1, a G2/M checkpoint...
5.
Quintanal-Villalonga A, Taniguchi H, Hao Y, Chow A, Zhan Y, Chavan S, et al.
Cancer Res . 2021 Nov; 82(3):472-483. PMID: 34815254
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past several decades has been platinum-based doublet...
6.
Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan S, Richards A, et al.
Nat Genet . 2021 Nov; 53(11):1577-1585. PMID: 34741162
Human cancers arise from environmental, heritable and somatic factors, but how these mechanisms interact in tumorigenesis is poorly understood. Studying 17,152 prospectively sequenced patients with cancer, we identified pathogenic germline...
7.
Caeser R, Hulton C, Costa E, Durani V, Little M, Chen X, et al.
iScience . 2021 Oct; 24(11):103224. PMID: 34712921
Activation of mitogenic signaling pathways is a common oncogenic driver of many solid tumors including lung cancer. Although activating mutations in the mitogen-activated protein kinase (MAPK) pathway are prevalent in...
8.
Quintanal-Villalonga A, Taniguchi H, Zhan Y, Hasan M, Chavan S, Meng F, et al.
J Hematol Oncol . 2021 Oct; 14(1):170. PMID: 34656143
Background: Lineage plasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lung adenocarcinomas (LUADs), this phenomenon includes small cell and squamous cell (LUSC) histologic...
9.
Salo-Mullen E, Maio A, Mukherjee S, Bandlamudi C, Shia J, Kemel Y, et al.
JCO Precis Oncol . 2021 Jul; 5. PMID: 34250384
Materials And Methods: Patients with pan-cancer (n = 11,081) underwent matched tumor-normal sequencing with consent for germline analysis. Medical records and tumors were reviewed and analyzed. Prevalence of PVs was...
10.
Quintanal-Villalonga A, Taniguchi H, Zhan Y, Hasan M, Chavan S, Meng F, et al.
Cancer Discov . 2021 Jun; 11(12):3028-3047. PMID: 34155000
Significance: The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here,...